Abstract
Atrasentan, an endothelin-A-receptor antagonist, did not delay in disease progression in men with metastatic hormone-refractory prostate cancer (HRPC), in a phase III randomised trial (Cancer, published online Sept 20, 2007; DOI:10.1002/cncr22996). The European Cancer Conference; Sept 23–27, 2007; Barcelona, SpainThe endothelin-A-receptor antagonist ZD4054 can improve overall survival (OS) in patients with pain-free or mildly symptomatic hormone-refractory prostate cancer (HRPC) who have bone metastases. In a double-blind phase II trial, Nick James (Birmingham, UK) and co-workers randomly assigned 312 patients in a 1:1:1 ratio to two different doses of ZD4054 or to placebo. No significant difference in progression-free survival (PFS) between treatment groups was noted. However, patients assigned ZD4054 has significantly improved OS compared with those assigned placebo (23·5 and 24·5 months vs 17·3 months). Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
